Bristol-Myers Squibb
The purpose of this study is to assess the safety, tolerability, efficacy, and drug levels of BMS-986548 as a monotherapy and in combination with anti-cancer agents in participants with advanced solid malignancies.
Inclusion Criteria * Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification). * Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Participants must have measurable disease assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. * Participants should have previously received, be ineligible for, or decline (after having been pro…
Specified dose on specified days
Specified dose on specified days
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.